Psividacor Cdi News - PVA

pSivida Plans Medidur™ EU Marketing Approval Application Based on Single Phase 3 Clinical Trial

WATERTOWN, Mass., Dec. 28, 2015 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader...

pSivida's Medidur™ Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurre...

Statistical Significance in Improvement in Visual Acuity and Reduction in Systemic Therapy ...

pSivida Corp. Provides Company Update and Reports First Quarter FY 2016 Results

WATERTOWN, Mass., Nov. 05, 2015 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV), (ASX:PVA), a leader...

pSivida Corp Announces First Quarter FY 2016 Financial Results Release Date and Conference Call Information

WATERTOWN, Mass., Oct. 30, 2015 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release...

pSivida Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs

Top-Line Data from First Trial Expected December 2015 pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained...

pSivida CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...

pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2015 Results

pSivida Corp. (NASDAQ: PSDV, ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases...

pSivida CEO Invited to Speak at Surfaces in BioMaterials Foundation’s BioInterface 2015 Annual Symposium

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...

pSivida Corp Announces Fourth Quarter and Fiscal Year 2015 Financial Results Release Date and Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...

pSivida CEO to Speak at Controlled Release Society Annual Meeting Workshop in Edinburgh, Scotland, This Weekend

pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases...

pSivida Announces Positive Top Line Results From Investigator-Sponsored Phase II Study of Medidur™ for Uveitis

Statistically Significant Reduction in Recurrence of Disease and Statistically Significant Improvement in Visual Acuity pSivida Corp...

pSivida Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur™ for Uveitis to Be Reported Next W...

Dr. Glenn J. Jaffe to Present at 33rd Annual Scientific Meeting of American Society of Retina Specialists pSivida Corp. (NASDAQ:PSDV...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Psividacor Cdi (PVA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

PVA News

pSivida Plans Medidur™ EU Marketing Approval Application Based on Single Phase 3 Clinical Trial

pSivida's Medidur™ Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurre...

pSivida Corp. Provides Company Update and Reports First Quarter FY 2016 Results

pSivida Corp Announces First Quarter FY 2016 Financial Results Release Date and Conference Call Information

pSivida Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs

pSivida CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015

pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2015 Results

pSivida CEO Invited to Speak at Surfaces in BioMaterials Foundation’s BioInterface 2015 Annual Symposium

pSivida Corp Announces Fourth Quarter and Fiscal Year 2015 Financial Results Release Date and Conference Call Information

pSivida CEO to Speak at Controlled Release Society Annual Meeting Workshop in Edinburgh, Scotland, This Weekend

pSivida Announces Positive Top Line Results From Investigator-Sponsored Phase II Study of Medidur™ for Uveitis

pSivida Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur™ for Uveitis to Be Reported Next W...

pSivida CEO to Present at ISOPT Clinical Meeting in Berlin in July 2015

pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur™ for Posterior Uveitis

pSivida Announces Two Tech Evaluation Agreements with Leading Global Pharmaceutical Company

PVA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Psividacor Cdi (PVA) News

Psividacor Cdi (PVA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

PVA News

pSivida Plans Medidur™ EU Marketing Approval Application Based on Single Phase 3 Clinical Trial

pSivida's Medidur™ Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurre...

pSivida Corp. Provides Company Update and Reports First Quarter FY 2016 Results

pSivida Corp Announces First Quarter FY 2016 Financial Results Release Date and Conference Call Information

pSivida Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs

pSivida CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015

pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2015 Results

pSivida CEO Invited to Speak at Surfaces in BioMaterials Foundation’s BioInterface 2015 Annual Symposium

pSivida Corp Announces Fourth Quarter and Fiscal Year 2015 Financial Results Release Date and Conference Call Information

pSivida CEO to Speak at Controlled Release Society Annual Meeting Workshop in Edinburgh, Scotland, This Weekend

pSivida Announces Positive Top Line Results From Investigator-Sponsored Phase II Study of Medidur™ for Uveitis

pSivida Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur™ for Uveitis to Be Reported Next W...

pSivida CEO to Present at ISOPT Clinical Meeting in Berlin in July 2015

pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur™ for Posterior Uveitis

pSivida Announces Two Tech Evaluation Agreements with Leading Global Pharmaceutical Company

PVA Discussion

Your Recent History